A detailed history of Black Rock Inc. transactions in Cardiff Oncology, Inc. stock. As of the latest transaction made, Black Rock Inc. holds 2,628,407 shares of CRDF stock, worth $10.3 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
2,628,407
Previous 677,458 287.98%
Holding current value
$10.3 Million
Previous $3.62 Million 61.32%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$2.22 - $5.89 $4.33 Million - $11.5 Million
1,950,949 Added 287.98%
2,628,407 $5.84 Million
Q1 2024

May 10, 2024

SELL
$1.46 - $5.91 $56,986 - $230,679
-39,032 Reduced 5.45%
677,458 $3.62 Million
Q4 2023

Feb 13, 2024

SELL
$0.96 - $1.55 $1,056 - $1,706
-1,101 Reduced 0.15%
716,490 $1.06 Million
Q3 2023

Nov 13, 2023

SELL
$1.38 - $2.18 $58,899 - $93,044
-42,681 Reduced 5.61%
717,591 $997,000
Q2 2023

Aug 11, 2023

BUY
$1.37 - $1.95 $3,361 - $4,785
2,454 Added 0.32%
760,272 $1.12 Million
Q1 2023

May 12, 2023

BUY
$1.45 - $2.09 $11,559 - $16,661
7,972 Added 1.06%
757,818 $1.25 Million
Q4 2022

Feb 13, 2023

BUY
$1.22 - $1.66 $912 - $1,241
748 Added 0.1%
749,846 $1.05 Million
Q3 2022

Nov 14, 2022

BUY
$1.54 - $3.21 $118,781 - $247,590
77,131 Added 11.48%
749,098 $1.15 Million
Q2 2022

Aug 12, 2022

SELL
$1.17 - $2.61 $2.13 Million - $4.76 Million
-1,824,153 Reduced 73.08%
671,967 $1.48 Million
Q1 2022

May 12, 2022

SELL
$2.11 - $7.25 $76,230 - $261,928
-36,128 Reduced 1.43%
2,496,120 $6.19 Million
Q4 2021

Feb 10, 2022

BUY
$5.18 - $7.24 $748,510 - $1.05 Million
144,500 Added 6.05%
2,532,248 $15.2 Million
Q3 2021

Nov 09, 2021

BUY
$5.01 - $7.58 $139,102 - $210,458
27,765 Added 1.18%
2,387,748 $15.9 Million
Q2 2021

Aug 11, 2021

BUY
$6.65 - $10.04 $15.7 Million - $23.7 Million
2,359,983 New
2,359,983 $15.7 Million

Others Institutions Holding CRDF

About Cardiff Oncology, Inc.


  • Ticker CRDF
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 43,334,900
  • Market Cap $170M
  • Description
  • Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; meta...
More about CRDF
Track This Portfolio

Track Black Rock Inc. Portfolio

Follow Black Rock Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.